▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1131 by analyst upside · 2026-06-27
MDXG
MiMedx Group, Inc.
Healthcare · Market Cap $585M · P/E 19.6x
ANALYST PRICE TARGET
+65.4%
implied upside to consensus target
Current Price $3.93
Consensus Target $6.5
Bull Target $8.0
Bear Target $5.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
0
Sell
0
52-Week Low $3.03
52-Week High $7.99
YTD Return -39.4%
FUNDAMENTALS
Market Cap $585M
P/E Ratio (TTM) 19.6x
Forward P/E 32.1x
EPS (TTM) $0.20
PEG Ratio 2.88
Dividend Yield N/A
Revenue (TTM) $389M
Profit Margin 7.9%
52-WEEK RANGE
52-Week Low $3.03
52-Week High $7.99
Current Price $3.93
Bear Target $5.0
Bull Target $8.0
● Now $3.93 ● Target $6.5
TRADING DATA
Avg Volume 1.5M
YTD Return -39.4%
Analyst Count 6
Consensus Buy
Upside to Target +65.4%
Last Updated 2026-06-27

ANALYST SUMMARY

MiMedx Group, Inc. (MDXG) is currently trading at $3.93 with a Wall Street consensus price target of $6.5, implying potential upside of 65.4% over the next 12 months. 6 analysts currently cover MDXG, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $5.0.

MDXG operates in the Healthcare sector with a market capitalisation of $585M. The stock is down 39.4% year-to-date and is currently trading near the lower end of its 52-week range of $3.03 – $7.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

BVS +51.3%
Bioventus Inc.
$663M · P/E 23.9x · Buy
KMDA +79.1%
Kamada Ltd.
$419M · P/E 20.7x · Buy
HSTM +19.7%
HealthStream, Inc.
$781M · P/E 38.2x · Buy
ZVRA +106.3%
Zevra Therapeutics, Inc.
$799M · P/E 6.6x · Buy
NRC +10.5%
NRC Health
$469M · P/E 52.0x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MDXG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-30 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-20 Building track record
Craig-Hallum — Reiterated
Buy → Buy 2026-04-17 Building track record
Citizens ● Initiated
Market Outperform 2026-02-23 Building track record
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-02-17 40% win rate (10 calls)
Lake Street — Reiterated
Buy → Buy 2026-01-20 27% win rate (11 calls)
Mizuho — Reiterated
Outperform → Outperform 2025-12-17 Building track record
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2025-07-31 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
15/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →